Whoop says it has over 50bn hours of continuous physiological data and expects around 4m members by year-end, per Will Ahmed.
Ahmed argues the shift from a 500 dollar device fee to a 15 to 30 dollar monthly subscription makes Whoop obsessed with retaining and engaging existing members rather than shipping new hardware.
Whoop is building its own foundational AI models on its data, now including blood tests and medical records, and its FDA dispute over blood pressure features remains unresolved.
Whoop bets constant wear and 50bn hours beat Apple
Whoop is betting that a wearable worn almost every hour of the day, paid for by subscription, builds a health data asset rivals cannot copy. Continuous measurement surfaces illnesses and behaviour effects that spot checks miss, and that data now trains Whoop's own models. The same ambition pushes Whoop toward medical territory, which is why it collided with the FDA.
Takeaways
Subscriptions keep Whoop focused on existing members. In 2017 Whoop dropped its one-time 500 dollar device fee for plans of 15 to 30 dollars a month. Ahmed says this made the company obsessed with engagement and rapid improvement, while hardware makers get pushed to ship new devices on fixed cycles.
Member growth is accelerating sharply. Founded in 2012, Whoop took about twelve years to reach one million members. It then took roughly eighteen months to reach two million and six more to reach three million, and it expects to end the year near 4m.
Round-the-clock wear creates the data moat. Members wear Whoop about 23.6 hours a day, producing over 50bn hours of physiological data. Whoop trains its own foundational models on it, now with blood tests and medical records, and may predict out-of-range biomarkers without measuring them directly.
Continuous signals catch serious illness early. A fit baseball player's sleeping heart rate hit 120 to 130 against a resting 50, leading to a stage four Hodgkin lymphoma diagnosis. Calacanis saw skin temperature two degrees high before an ER visit and caught COVID early enough for Paxlovid.
Journaling and AI turn data into behaviour change. Over half of members journal daily across 100+ behaviours, and about 80 percent use the AI coach, launched under six months ago. Alcohol and late meals are the biggest negatives. Calacanis found warm baths lift his recovery 7 percent.
The FDA fight centers on blood pressure. Whoop built a blood pressure feature from a 70,000-member study and launched it as wellness, drawing an FDA warning letter. The agency later updated guidance to allow wellness uses. Whoop pursues both routes, with its ECG feature FDA-cleared.
Athletes became marketing after years unpaid. LeBron James, among Whoop's first 100 wearers, became a global ambassador after eleven years. Whoop avoided paying athletes early and now uses likenesses in ads. Leagues still resist, with the Australian Open removing devices despite International Tennis Federation approval.
Calacanis on syndicates and secondaries
His syndicate has 4,000 members and backed Zipline and ICON, which he calls billion dollar companies.
Tap a name to go there · tap a line to see why they are linked
On this episode 2
Show 1
He advises building a relationship with a company's CFO and getting their blessing before doing SPV deals.
When Masayoshi Son told Uber investors to sell or he would back Lyft, Calacanis sold him 10 percent of his shares.
He says the anti-AI trade is hitting companies such as DoorDash, Uber and Figma, though some are unaffected.